- Home
- PROK vs HYLN Comparison
PROK vs HYLN Comparison
Compare PROK & HYLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | HYLN |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.2M | 348.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PROK | HYLN |
|---|---|---|
| Price | $2.09 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $7.40 | $5.00 |
| AVG Volume (30 Days) | ★ 844.7K | 798.2K |
| Earning Date | 02-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.88 |
| EPS | ★ N/A | N/A |
| Revenue | $76,000.00 | ★ $1,509,000.00 |
| Revenue This Year | $1,010.19 | $204.64 |
| Revenue Next Year | N/A | $173.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 124.55 |
| 52 Week Low | $0.46 | $1.11 |
| 52 Week High | $7.13 | $2.56 |
Technical Indicators
Market Signals| Indicator | PROK | HYLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 48.86 |
| Support Level | $1.87 | $2.00 |
| Resistance Level | $2.23 | $2.17 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 86.47 | 50.00 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.